302 related articles for article (PubMed ID: 32013816)
1. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
2. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
[TBL] [Abstract][Full Text] [Related]
4. HDAC Inhibitors as Novel Anti-Cancer Therapeutics.
De Souza C; Chatterji BP
Recent Pat Anticancer Drug Discov; 2015; 10(2):145-62. PubMed ID: 25782916
[TBL] [Abstract][Full Text] [Related]
5. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
[TBL] [Abstract][Full Text] [Related]
6. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Son DS; Wilson AJ; Parl AK; Khabele D
Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
[TBL] [Abstract][Full Text] [Related]
7. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
8. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.
Wang C; Henkes LM; Doughty LB; He M; Wang D; Meyer-Almes FJ; Cheng YQ
J Nat Prod; 2011 Oct; 74(10):2031-8. PubMed ID: 21793558
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Khabele D; Son DS; Parl AK; Goldberg GL; Augenlicht LH; Mariadason JM; Rice VM
Cancer Biol Ther; 2007 May; 6(5):795-801. PubMed ID: 17387270
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors from microorganisms: the Astellas experience.
Masuoka Y; Shindoh N; Inamura N
Prog Drug Res; 2008; 66():335, 337-59. PubMed ID: 18416310
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
12. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Petrich A; Nabhan C
Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
[TBL] [Abstract][Full Text] [Related]
13. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
14. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
Thaler F
Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide.
Mizutani H; Hiraku Y; Tada-Oikawa S; Murata M; Ikemura K; Iwamoto T; Kagawa Y; Okuda M; Kawanishi S
Cancer Sci; 2010 Oct; 101(10):2214-9. PubMed ID: 20624163
[TBL] [Abstract][Full Text] [Related]
16. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
Yurek-George A; Cecil AR; Mo AH; Wen S; Rogers H; Habens F; Maeda S; Yoshida M; Packham G; Ganesan A
J Med Chem; 2007 Nov; 50(23):5720-6. PubMed ID: 17958342
[TBL] [Abstract][Full Text] [Related]
17. The biology of HDAC in cancer: the nuclear and epigenetic components.
Hagelkruys A; Sawicka A; Rennmayr M; Seiser C
Handb Exp Pharmacol; 2011; 206():13-37. PubMed ID: 21879444
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitor-based therapies: can we interpret the code?
New M; Olzscha H; La Thangue NB
Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
20. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]